XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation

XenaCare Holdings has announced that it has become a national sponsor of the Arthritis Foundation, one of the largest nonprofit organizations dedicated to arthritis research and public health education.

Delray Beach, FL (Vocus) November 28, 2009

XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that is has become a national sponsor of the Arthritis Foundation at the National Proud Sponsor level.

“As one of the largest and most well-respected nonprofit organizations dedicated to arthritis research and public health education, the Arthritis Foundation is on an important mission to improve the quality of life for millions of people around the world suffering from more than 100 different types of arthritis,” explained Frank Rizzo, President of XenaCare Holdings. “We are honored to be associated with the Arthritis Foundation as a national sponsor and we look forward to continuing to work closely with the Organization to help support their ongoing efforts,” he added.

With the sponsorship of the Arthritis Foundation, Cobroxin may bear the Arthritis Foundation Proud Sponsor Logo on its packaging. This logo illustrates to consumers that Cobroxin is proud to support the Arthritis Foundation's efforts to help people take control of arthritis. Additionally, the Arthritis Foundation will work with XenaCare and other Proud Sponsors to help build awareness about Cobroxin through its magazine, Arthritis Today, its membership e-newsletter and on its website, Arthritis.org.

The National Proud Sponsor program represents the highest level of collaboration with the Arthritis Foundation. According to the Arthritis Foundation, Proud Sponsors provide critical support of the Foundation's key mission areas including:

• Advocacy - Local, state and national efforts to advance vital legislation.
• Research - Cutting edge, peer-reviewed research that has the greatest potential for advancement in the search for a cure.
• Public health - Information and empowering programs and services.
• Community-based outreach - Network of 42 chapter offices

In 2009, XenaCare received the exclusive license from biotechnology company, Nutra Pharma Corporation (OTCBB: NPHC), to market and distribute Cobroxin throughout the United States. Cobroxin is clinically proven to treat moderate to severe (Stage 2) chronic pain and is currently available for sale at several retailers, including online at Cobroxin.com.

About XenaCare Holdings

XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States.

In 2009, the Company received the exclusive license to market and distribute Cobroxin within the United States. Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation that is clinically proven to treat moderate to severe (Stage 2) pain. The drug, which recently won the award for “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference held in Miami, Florida, is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating repetitive stress, arthritis, and joint pain.

Benefits to Cobroxin include:

• All Natural
• Non-Addictive
• Non-Narcotic
• Non-Opiate
• More Potent than Morphine
• Long Lasting

http://www.XenaCareHoldings.com
http://www.Cobroxin.com

Cautionary Note Concerning Forward Looking Statements
Except for the historical and present factual information contained herein, the matters set forth in this document, including statements regarding our plans to introduce Cobroxin into the commercial marketplace and for additional marketing campaigns are forward looking statements. Although these forward looking statements constitute our current plans, the timing, marketing channels and advertising support for the product may change. Investors are cautioned that these forward-looking statements are not guarantees of future performance. Actual events or results may differ from the Company’s current plans. There are many risks, uncertainties and other factors that can prevent the achievement of our goals or cause results to differ from those expressed or implied by these forward-looking statements including, without limitation, the risks described in greater detail in filings made by the Company with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future events make it clear that any of the anticipated results expressed or implied herein will not be realized. The Company's filings may be accessed at the SEC's Edgar system at http://www.sec.gov.

###